You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》富瑞:HARMONi試驗印證中國數據可信度 予康方生物(09926.HK)目標價150元
阿思達克 06-02 15:34
富瑞研究報告指,康方生物(09926.HK)日前公布,與合作夥伴Summit Therapeutics(SMMT.US)合作的HARMONi全球試驗,證明中國的數據可轉化至全球,對於所有中國生物科技公司的對外授權都至關重要。雖然市場憂慮對於整體生存期(OS)的監管會更為嚴格,但該行並不擔心,因為中國以外的OS數據成熟度不到50%,Summit Therapeutics將根據進一步的OS數據發展來安排提交生物製劑許可申請(BLA)。 在聯合化療(chemo combo)方面,康方生物將會盡快推進關鍵適應症的開發,以進一步鞏固AK112在中國的領先地位;而在ADC藥物的戰略方面,公司正在積極探索尋求合作夥伴,同時開發內部雙特異性ADC候選藥物。 另外,Summit Therapeutics亦在研究聯合化療,包括與輝瑞(PFE.US)合作。鑑於PD-1/VEGF模式的安全性和有效性已得到證明,該行認為Summit Therapeutics有可能再次成為收購目標,特別是近期股價回調後,估值明顯降低且更合理。該行現予康方生物目標價150元及「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account